[go: up one dir, main page]

PE20130210A1 - Composicion farmaceutica solida que comprende un derivado de bencimidazol y un agente de control de ph - Google Patents

Composicion farmaceutica solida que comprende un derivado de bencimidazol y un agente de control de ph

Info

Publication number
PE20130210A1
PE20130210A1 PE2012001692A PE2012001692A PE20130210A1 PE 20130210 A1 PE20130210 A1 PE 20130210A1 PE 2012001692 A PE2012001692 A PE 2012001692A PE 2012001692 A PE2012001692 A PE 2012001692A PE 20130210 A1 PE20130210 A1 PE 20130210A1
Authority
PE
Peru
Prior art keywords
pharmaceutical composition
control agent
composition including
benzhimidazole
derivative
Prior art date
Application number
PE2012001692A
Other languages
English (en)
Inventor
Shuji Yoneyama
Yutaka Tanoue
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39590787&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20130210(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of PE20130210A1 publication Critical patent/PE20130210A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UN ANTAGONISTA DEL RECEPTOR DE ANGIOTENSINA II TAL COMO EL COMPUESTO (5-METIL-2-OXO-1,3-DIOXOL-4-IL)METIL-2-ETOXI-1-{[2'-(5-OXO-4,5-DIHIDRO-1,2,4-OXADIAZOL-3-IL)BIFENIL-4-IL]METIL}-1H-BENCIMIDAZOL-7-CARBOXILATO O UNA SAL DE POTASIO DEL MISMO; Y B) UN AGENTE DE CONTROL DE PH QUE PRESENTA UN PH DE 2 A 5 TAL COMO FUMARATO MONOSODICO O UNA COMBINACION DE ACIDO FUMARICO E HIDROXIDO DE SODIO
PE2012001692A 2007-03-28 2008-03-26 Composicion farmaceutica solida que comprende un derivado de bencimidazol y un agente de control de ph PE20130210A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90851507P 2007-03-28 2007-03-28

Publications (1)

Publication Number Publication Date
PE20130210A1 true PE20130210A1 (es) 2013-03-11

Family

ID=39590787

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2012001692A PE20130210A1 (es) 2007-03-28 2008-03-26 Composicion farmaceutica solida que comprende un derivado de bencimidazol y un agente de control de ph
PE2008000540A PE20090550A1 (es) 2007-03-28 2008-03-26 Composicion farmaceutica solida que comprende un derivado de bencimidazol y un agente de control de ph

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2008000540A PE20090550A1 (es) 2007-03-28 2008-03-26 Composicion farmaceutica solida que comprende un derivado de bencimidazol y un agente de control de ph

Country Status (19)

Country Link
US (1) US9066936B2 (es)
EP (1) EP2124903B1 (es)
JP (1) JP5283632B2 (es)
KR (1) KR20090125846A (es)
CN (1) CN101677961B (es)
AR (1) AR065850A1 (es)
AU (1) AU2008235790B2 (es)
BR (1) BRPI0809522A2 (es)
CA (1) CA2681143C (es)
CL (1) CL2008000868A1 (es)
EA (1) EA016593B1 (es)
ES (1) ES2743784T3 (es)
IL (1) IL201188A0 (es)
MX (1) MX2009010167A (es)
NZ (1) NZ579851A (es)
PE (2) PE20130210A1 (es)
PT (1) PT2124903T (es)
TW (1) TWI415634B (es)
WO (1) WO2008123536A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2732018C (en) 2008-07-31 2017-07-04 Takeda Pharmaceutical Company Limited Solid pharmaceutical composition
TW201014850A (en) * 2008-09-25 2010-04-16 Takeda Pharmaceutical Solid pharmaceutical composition
KR20140030237A (ko) * 2011-05-23 2014-03-11 지앙수 헨그루이 메디슨 컴퍼니 리미티드 벤즈이미다졸 유도체를 함유하는 고체 약제학적 조성물
CN102351853B (zh) * 2011-08-29 2014-03-12 石药集团欧意药业有限公司 一种阿齐沙坦酯化合物、制备方法及其药物组合物
JP5791817B2 (ja) 2012-09-19 2015-10-07 大鵬薬品工業株式会社 溶出性及び／又は吸収性が改善された経口投与用医薬組成物
WO2014088123A1 (en) 2012-12-05 2014-06-12 Sawai Pharmaceutical Co., Ltd. Candesartan cilexetil-containing preparation
WO2014102628A1 (en) 2012-12-31 2014-07-03 Ranbaxy Laboratories Limited Stable pharmaceutical composition comprising azilsartan medoxomil
JP6379043B2 (ja) 2013-01-30 2018-08-22 沢井製薬株式会社 カンデサルタンシレキセチル含有医薬組成物
CN105079815A (zh) * 2014-04-30 2015-11-25 广东东阳光药业有限公司 一种阿齐沙坦酯钾组合物及其制备方法
IN201721047406A (es) 2017-12-30 2020-06-19 Lupin Limited
IN202021028444A (es) * 2020-07-03 2022-01-28
CN117122570B (zh) * 2022-05-19 2024-04-09 北京阳光诺和药物研究股份有限公司 一种提高稳定性的美阿沙坦钾片及其制备方法
WO2024109927A1 (zh) * 2022-11-24 2024-05-30 上海云晟研新生物科技有限公司 包含美阿沙坦钾与钙通道阻滞剂的药物组合物，及其制备方法及应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250554A (en) * 1989-10-24 1993-10-05 Takeda Chemical Industries, Ltd. Benzimidazole derivatives useful as angiotensin II inhibitors
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US6004989A (en) * 1990-04-27 1999-12-21 Takeda Chemical Industries, Ltd. Benzimidazole derivatives, their production and use
US5703110A (en) * 1990-04-27 1997-12-30 Takeda Chemical Industries, Ltd. Benzimidazole derivatives, their production and use
IL102183A (en) * 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd Biphenyl substituted heterocyclic compounds their production and pharmaceutical compositions comprising them
TW284688B (es) * 1991-11-20 1996-09-01 Takeda Pharm Industry Co Ltd
CA2115985A1 (en) * 1993-02-25 1994-08-26 Kohei Nishikawa Vascular hypertrophy suppressor
JP2787539B2 (ja) * 1993-02-26 1998-08-20 松森　　昭 ウイルス性疾患の予防または治療剤
JP3810020B2 (ja) * 1993-04-22 2006-08-16 武田薬品工業株式会社 腎疾患の予防または治療剤
US5721263A (en) * 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
CZ154994A3 (en) * 1993-07-02 1995-09-13 Senju Pharma Co Visual hypotensive agent
CN1215338A (zh) * 1996-04-05 1999-04-28 武田药品工业株式会社 包含具有血管紧张素ⅱ拮抗活性的化合物的药物组合物
BR9908474A (pt) * 1998-03-04 2000-12-05 Takeda Chemical Industries Ltd Preparação de liberação prolongada, processo para a produção de uma preparação de liberação prolongada, e, composição farmacêutica
AU2573800A (en) * 1999-02-19 2000-09-04 Takeda Chemical Industries Ltd. Percutaneous absorption preparations of compound having angiotensin ii receptor antagonism
SI1197223T1 (es) * 1999-04-28 2005-08-31 Takeda Pharmaceutical
JP2001089393A (ja) * 1999-07-21 2001-04-03 Takeda Chem Ind Ltd 脳血管障害の再発予防剤および脳血管障害の後遺症の改善・進展抑制剤
EP1262180A4 (en) * 2000-02-18 2005-06-01 Takeda Pharmaceutical TNF-ALPHA INHIBITORS
WO2001060410A1 (fr) * 2000-02-21 2001-08-23 Takeda Chemical Industries, Ltd. Preparations a liberation lente contenant un compose physiologiquement actif peu soluble dans l'eau et methode de production et d'utilisation desdites preparations
JP2001316296A (ja) * 2000-02-21 2001-11-13 Takeda Chem Ind Ltd 水に難溶性の生理活性化合物の徐放性製剤、その製造法および用途
EP1444988A4 (en) * 2001-11-13 2007-04-25 Takeda Pharmaceutical CANCER AGENT
AU2002349673A1 (en) 2001-12-03 2003-06-17 Takeda Chemical Industries, Ltd. Insulin resistance improving agents
JP4484427B2 (ja) * 2001-12-03 2010-06-16 武田薬品工業株式会社 インスリン抵抗性改善剤
ATE551056T1 (de) * 2002-12-27 2012-04-15 Takeda Pharmaceutical Mittel zur hemmung der körpergewichtszunahme
EP1607092A4 (en) * 2003-03-17 2010-12-15 Takeda Pharmaceutical COMPOSITIONS WITH CONTROLLED RELEASE
US7157584B2 (en) 2004-02-25 2007-01-02 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use thereof
WO2005117591A2 (en) * 2004-05-28 2005-12-15 Andrx Labs Llc Novel pharmaceutical formulation containing a biguanide and an angiotensin antagonist
EP1787647B1 (en) * 2004-09-06 2012-06-20 Kowa Company, Ltd. Remedy for glomerular diseases
US20060159747A1 (en) * 2004-12-17 2006-07-20 Boehringer Ingelheim International Gmbh Telmisartan and hydrochlorothiazide combination therapy
JP2008540573A (ja) * 2005-05-13 2008-11-20 マイクロビア インコーポレーテッド ４−ビアリーリル−１−フェニラゼチジン−２−オン類
CN101247832B (zh) * 2005-06-27 2011-12-28 第一三共株式会社 含有血管紧张素ⅱ受体拮抗剂和钙通道阻断剂的药物制剂
DE102005031577A1 (de) 2005-07-06 2007-01-11 Bayer Healthcare Ag Pharmazeutische Darreichungsformen enthaltend eine Wirkstoffkombination von Nifedipin und/oder Nisoldipin und einem Angiotensin-II Antagonisten
TWI494134B (zh) 2006-06-20 2015-08-01 Siegfried Generics Int Ag 含有坎地沙坦酯的組成物、錠劑和顆粒及該錠劑的製造方法
WO2008045006A1 (en) * 2006-10-11 2008-04-17 Fako Ilaclari A. S. Formulations of candesartan
WO2008068217A2 (en) * 2006-12-04 2008-06-12 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a coated hmg-coa reductase inhibitor and an inhibitor of the renin-angiotensin system
US9387249B2 (en) * 2008-12-23 2016-07-12 Takeda Pharmaceutical Company Limited Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone

Also Published As

Publication number Publication date
JP5283632B2 (ja) 2013-09-04
CL2008000868A1 (es) 2008-10-10
TW200902089A (en) 2009-01-16
EA200970896A1 (ru) 2010-04-30
CN101677961A (zh) 2010-03-24
BRPI0809522A2 (pt) 2014-10-14
IL201188A0 (en) 2010-05-17
AR065850A1 (es) 2009-07-08
ES2743784T3 (es) 2020-02-20
AU2008235790B2 (en) 2013-06-06
CA2681143C (en) 2017-01-03
CA2681143A1 (en) 2008-10-16
US20100121071A1 (en) 2010-05-13
PE20090550A1 (es) 2009-06-01
EP2124903A1 (en) 2009-12-02
WO2008123536A1 (en) 2008-10-16
US9066936B2 (en) 2015-06-30
TWI415634B (zh) 2013-11-21
JP2010522692A (ja) 2010-07-08
CN101677961B (zh) 2012-10-17
PT2124903T (pt) 2019-09-26
AU2008235790A1 (en) 2008-10-16
KR20090125846A (ko) 2009-12-07
EA016593B1 (ru) 2012-06-29
NZ579851A (en) 2012-02-24
EP2124903B1 (en) 2019-06-12
MX2009010167A (es) 2009-10-12

Similar Documents

Publication Publication Date Title
PE20130210A1 (es) Composicion farmaceutica solida que comprende un derivado de bencimidazol y un agente de control de ph
MX2010005997A (es) Derivados de aminobenzamida como agentes utiles para el control de parasitos de animales.
CL2011000558A1 (es) Formas cristalinas de un compuesto derivado de 2-tiazolil-4-quinolinil-oxi; sal de sodio del compuesto, composicion farmaceutica que comprende la sal de sodio, util para tratar una infeccion por el virus de la hepatitis c.
EA201101672A1 (ru) Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина
MX2011012628A (es) Derivados amino-propionicos sustituidos como inhibidores de neprilisina.
AR072261A1 (es) Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos.
UA105229C2 (uk) Фармацевтичний склад
TW200833370A (en) Pharmaceutical composition containing low substituted hydroxypropylcellulose
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
TN2012000125A1 (en) Substituted carbamoylmethylamino acetic acid derivatives as novel nep inhibitors
BRPI0714315B8 (pt) arilamidas substituídas com tetrazol, seu uso e composição farmacêutica que as compreende
MX2013005533A (es) Derivados de acido amino-bisfenil-pentanoico sustituidos como inhibidores de nep.
MX2022001655A (es) Dispersiones solidas que comprenden estimulador de heme guanilato ciclasa soluble (sgc).
GB0607954D0 (en) Organic compounds
GEP20135744B (en) Quinuclidine carbonate derivatives and medicinal compositions containing the same
CR20110209A (es) Composición farmacéutica sólida
TW200801022A (en) Novel amino alcohol-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments
PH12015501752B1 (en) Substituted bisphenyl butanoic phosphonic acid derivatives as nep inhibitors
MA33945B1 (fr) Procédés de fabrication d'un principe pharmaceutiquement actif
ATE496918T1 (de) Als a2b-adenosinrezeptorantagonisten geeignete 5- phenyl-6-pyridin-4-yl-1,3-dihydro-2h-imidazoä4, - büpyridin-2-onderivate
PH12012500992A1 (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
CL2011000187A1 (es) Preparacion farmaceutica que comprende (5-metil-2-oxo-1,3-dioxol-4il)metil 2-etoxi-1-{[2,{5-oxo-4,5-dihidro-1,2,4-oxadiazol-3-il)bifenil4il]metil}-1h-benzimidazol-7-carboxilato, un agente de control de ph entre 2 y 5 y un diuretico; metodo para estabilizar; metodo para mejorar disolucion, util en enfermedades inducidas por angiotensina ii.
MY157492A (en) Pharmaceutical composition 271
MX353991B (es) Agonista del receptor de 5-ht4 como agente procinetico.
PE20120249A1 (es) Compuestos etanaminicos

Legal Events

Date Code Title Description
FD Application declared void or lapsed